133results about How to "Maximize the effect of treatment" patented technology

A method of treating regurgitation of a mitral valve in a patient's heart. The method includes the steps of: delivering a tissue shaping device to the coronary sinus; and deploying the tissue shaping device to reduce mitral valve regurgitation, the deploying step comprising applying a force through the coronary sinus wall toward the mitral valve solely proximal to a crossover point where a coronary artery passes between a coronary sinus and the mitral valve. The invention is also a set of devices for use in treating mitral valve regurgitation. The set includes a plurality of tissue shaping devices having different lengths, each of the tissue shaping devices being configured to be deliverable to a coronary sinus of a patient within a catheter having an outer diameter no greater than ten french.

A tissue shaping device adapted to be disposed in a vessel near a patient's heart to reshape the patient's heart. The tissue shaping device includes a proximal anchor, a distal anchor, and a connector disposed between the proximal anchor and the distal anchor, the connector having a moment of inertia that varies along its length, such as by varying the connector thickness as a function of distance from one of its ends, with the smallest thickness being in the central portion of the connector.

A tissue shaping device adapted to be deployed in a vessel to reshape tissue adjacent to the vessel. In some embodiments the device includes a distal anchor having a flexible wire with at least one bending point and first and second arms extending from the bending point, the first and second arms being adapted to deform about the bending point; a proximal anchor having a flexible wire with at least one bending point and first and second arms extending from the bending point, the first and second arms being adapted to deform about the bending point; and a connector disposed between the distal anchor and the proximal anchor.

One aspect of the invention is a method of treating mitral valve regurgitation in a patient. The method includes the steps of delivering a tissue shaping device to the patient's coronary sinus in an unexpanded configuration within a catheter having an outer diameter no more than nine or ten french, with the tissue shaping device including a connector disposed between a distal expandable anchor comprising flexible wire and a proximal expandable anchor comprising flexible wire, the device having a length of 60 mm or less; and deploying the device to reduce mitral valve regurgitation, such as by anchoring the distal expandable anchor by placing the distal expandable anchor flexible wire in contact with a wall of the coronary sinus, e.g., by permitting the distal expandable anchor to self-expand or by applying an actuating force to the distal expandable anchor and possibly locking the distal expandable anchor after performing the applying step. The invention also includes a device for performing the method.

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

An implantable, time-released substance delivery device includes a casing having an exterior surface, and a number of pores disposed on the exterior surface of the casing. The time-released substance delivery device further has an interior chamber disposed within the casing, and a number of excretion tubes disposed within the casing. Each of the excretion tubes fluidly connects the interior chamber to one of the pores.

An apparatus and method for providing treatment feedback relating to a patient undergoing therapeutic treatment of tissue during dynamic motion therapy are provided. The apparatus includes a platform configured to support a body of the patient; an oscillator connected to the platform and configured to impart an oscillating force at a predetermined frequency on the platform for transmitting mechanical vibration energy through the patient's body; and a processing device in operable communication with the platform for processing data related to the therapeutic treatment and for determining the amount of mechanical vibration energy transmitting through the patient's body. The apparatus further includes a treatment feedback indicator for indicating (e.g., displaying) the amount of mechanical vibration energy transmitting through the patient's body.

An introducing device for locating a tissue region and deploying an electrode is shown and described. The introducing device may include an outer sheath. An inner sheath may be disposed within the outer sheath. The inner sheath may be configured to engage an implantable electrode. In an example, the inner sheath may comprise a stimulation probe having an uninsulated portion at or near a distal end of the delivery sheath. The outer sheath may be coupled to a power source or stimulation signal generating circuitry at a proximal end. A clinician may control application of the stimulation signal to a tissue region via the outer sheath.

New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of at least one pharmaceutically active ingredient capable of intraoral administration; and (b) as a second portion located around the said first portion, a therapeutically effective amount of at least one pharmaceutically active ingredient capable of oral administration and which is releasable and orally ingestible by the patient after the molded triturate tablet has disintegrated or has dissolved intraorally.

The invention comprises a treatment probe and method delivering radiofrequency stimulation for controlled heating of tissue within the vagina to treat vaginal laxity. The treatment probe includes a rounded disposable treatment tip to accommodate the anatomy of the vagina which is coupled with an electrode assembly, both of which are assembled to transfer radiofrequency energy to vaginal surface and subsurface. The treatment tip includes a skin temperature sensor that monitors skin temperature to maintain a pre-set treatment temperature; the entire assembly is connected to a reusable treatment probe handle and radiofrequency generator.